Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Head and Neck Cancer

  Free Subscription

Articles published in Gastrointest Endosc

Retrieve available abstracts of 64 articles:
HTML format

Single Articles

    December 2022
  1. MCDONALD OG, Montgomery EA
    Artificial intelligence for dysplasia grading in Barrett's esophagus: hematoxylin and eosin is here to stay.
    Gastrointest Endosc. 2022;96:926-928.

  2. FAGHANI S, Codipilly DC, David Vogelsang, Moassefi M, et al
    Development of a deep learning model for the histologic diagnosis of dysplasia in Barrett's esophagus.
    Gastrointest Endosc. 2022;96:918-925.
    PubMed     Abstract available

    November 2022
  3. FREDERIKS CN, Overwater A, Alvarez Herrero L, Alkhalaf A, et al
    Comparison of focal cryoballoon ablation with 10- and 8-second doses for treatment of Barrett's esophagus-related neoplasia: results from a prospective European multicenter study (with video).
    Gastrointest Endosc. 2022;96:743-751.
    PubMed     Abstract available

    October 2022
  4. MINAMIDE T, Kawata N, Maeda Y, Yoshida M, et al
    Clinical outcomes of endoscopic submucosal dissection for superficial circumferential esophageal squamous cell carcinoma.
    Gastrointest Endosc. 2022 Oct 10. pii: S0016-5107(22)02035.
    PubMed     Abstract available

    September 2022
  5. DENG K, Jing W, Chen M
    More prognostic information may be harvested in the subgroup analysis of esophageal adenocarcinoma unrelated death.
    Gastrointest Endosc. 2022;96:566.

  6. FAN X, Wu Q, Li R, Chen W, et al
    Clinical benefit of tunnel endoscopic submucosal dissection for esophageal squamous cancer: a multicenter, randomized controlled trial.
    Gastrointest Endosc. 2022;96:436-444.
    PubMed     Abstract available

    August 2022
  7. KAMBOJ AK, Iyer PG
    Pushing the boundaries of endoscopic management of early-stage esophageal adenocarcinoma: Caution is advisable!
    Gastrointest Endosc. 2022;96:248-249.

    Solving the puzzle of optimal surveillance after endoscopic eradication therapy of Barrett's esophagus.
    Gastrointest Endosc. 2022;96:234-236.

  9. WONG MCS, Deng Y, Huang J, Bai Y, et al
    Performance of screening tests for esophageal squamous cell carcinoma: a systematic review and meta-analysis.
    Gastrointest Endosc. 2022;96:197-207.
    PubMed     Abstract available

  10. NIEUWENHUIS EA, van Munster SN, Meijer SL, Brosens LAA, et al
    Analysis of metastases rates during follow-up after endoscopic resection of early "high-risk" esophageal adenocarcinoma.
    Gastrointest Endosc. 2022;96:237-247.
    PubMed     Abstract available

  11. WOLFSON P, Ho KMA, Wilson A, McBain H, et al
    Endoscopic eradication therapy for Barrett's esophagus-related neoplasia: a final 10-year report from the UK National HALO Radiofrequency Ablation Registry.
    Gastrointest Endosc. 2022;96:223-233.
    PubMed     Abstract available

    July 2022
  12. LIU K, Aadam AA
    T1b esophageal cancer: Is it time for endoscopic submucosal dissection to enter the stage?
    Gastrointest Endosc. 2022 Jul 18. pii: S0016-5107(22)01681.

    June 2022
  13. CHAN MW, Pouw RE
    Risk-stratification models for Barrett's esophagus: Will we get to the perfect classifier?
    Gastrointest Endosc. 2022;95:1123-1125.

  14. THOTA PN, Nasibli J, Kumar P, Sanaka MR, et al
    Prediction of neoplastic progression in Barrett's esophagus using nanoscale nuclear architecture mapping: a pilot study.
    Gastrointest Endosc. 2022;95:1239-1246.
    PubMed     Abstract available

  15. NGUYEN TH, Thrift AP, Ketwaroo GA, Du XL, et al
    External validation of a model determining risk of neoplastic progression of Barrett's esophagus in a cohort of U.S. veterans.
    Gastrointest Endosc. 2022;95:1113-1122.
    PubMed     Abstract available

  16. DEMEESTER S, Smith C, Severson P, Loveitt A, et al
    Multicenter randomized controlled trial comparing forceps biopsy sampling with wide-area transepithelial sampling brush for detecting intestinal metaplasia and dysplasia during routine upper endoscopy.
    Gastrointest Endosc. 2022;95:1101-1110.
    PubMed     Abstract available

    April 2022
  17. YANG D, King W, Aihara H, Karasik MS, et al
    Effect of endoscopic submucosal dissection on histologic diagnosis in Barrett's esophagus visible neoplasia.
    Gastrointest Endosc. 2022;95:626-633.
    PubMed     Abstract available

    March 2022
    What's next for wide-area transepithelial sampling in Barrett's esophagus management?
    Gastrointest Endosc. 2022;95:419-421.

  19. AGARWAL S, Alshelleh M, Scott J, Dhaliwal L, et al
    Comparative outcomes of radiofrequency ablation and cryoballoon ablation in dysplastic Barrett's esophagus: a propensity score-matched cohort study.
    Gastrointest Endosc. 2022;95:422-431.
    PubMed     Abstract available

  20. SHAHEEN NJ, Smith MS, Odze RD
    Progression of Barrett's esophagus, crypt dysplasia, and low-grade dysplasia diagnosed by wide-area transepithelial sampling with 3-dimensional computer-assisted analysis: a retrospective analysis.
    Gastrointest Endosc. 2022;95:410-418.
    PubMed     Abstract available

    February 2022
  21. XU JQ, Zhang ZC, Chen WF, Xu MD, et al
    Repeated endoscopic submucosal dissection (ESD) as salvage treatment for local recurrence of esophageal squamous cell carcinoma after initial ESD.
    Gastrointest Endosc. 2022 Feb 28. pii: S0016-5107(22)00182.
    PubMed     Abstract available

  22. JOSEPH A, Draganov P, Maluf-Filho F, Aihara H, et al
    Outcomes for ESD of Pathologically Staged T1b Esophageal Cancer: A Multi-Center Study.
    Gastrointest Endosc. 2022 Feb 22. pii: S0016-5107(22)00123.
    PubMed     Abstract available

  23. HONING J, di Pietro M
    Surveillance for Barrett's esophagus: let's get the basics right.
    Gastrointest Endosc. 2022;95:246-248.

  24. PARASA S, Wallace MB, Srinivasan S, Sundaram S, et al
    Educational intervention to improve quality of care in Barrett's esophagus: the AQUIRE randomized controlled trial.
    Gastrointest Endosc. 2022;95:239-245.
    PubMed     Abstract available

  25. GUO Q, Fan X, Zhu S, Zhao X, et al
    Comparing N-acetylcysteine with sodium thiosulfate for relieving symptoms caused by Lugol's iodine chromoendoscopy: a randomized, double-blind trial.
    Gastrointest Endosc. 2022;95:249-257.
    PubMed     Abstract available

    January 2022
  26. CODIPILLY DC, Krishna Chandar A, Wang KK, Katzka DA, et al
    Wide-area transepithelial sampling for dysplasia detection in Barrett's esophagus: a systematic review and meta-analysis.
    Gastrointest Endosc. 2022;95:51-59.
    PubMed     Abstract available

  27. ADLER DG
    Esophageal papillomatosis presenting with complete esophageal obstruction and high positron emission tomography avidity.
    Gastrointest Endosc. 2022;95:187-188.

  28. FARHA N, Hrabe J, Sleiman J, Beard J, et al
    Clinically actionable findings on surveillance EGD in asymptomatic patients with Lynch syndrome.
    Gastrointest Endosc. 2022;95:105-114.
    PubMed     Abstract available

    December 2021
  29. TANAKA I, Hirasawa D, Matsuda T
    Extremely small but invasive esophageal cancer: endoscopists should not miss it.
    Gastrointest Endosc. 2021 Dec 1. pii: S0016-5107(21)01847.

    November 2021
  30. SATO D, Kadota T, Inaba A, Nishihara K, et al
    Long-term clinical outcome after endoscopic resection of esophageal squamous cell carcinoma invading the muscularis mucosae without lymphovascular invasion.
    Gastrointest Endosc. 2021 Nov 10. pii: S0016-5107(21)01781.
    PubMed     Abstract available

  31. FALK GW
    Low-grade dysplasia in Barrett's esophagus: More than meets the eye?
    Gastrointest Endosc. 2021;94:909-911.

  32. TSOI EH, Mahindra P, Cameron G, Williams R, et al
    Barrett's esophagus with low-grade dysplasia: high rate of upstaging at Barrett's esophagus referral units suggests progression rates may be overestimated.
    Gastrointest Endosc. 2021;94:902-908.
    PubMed     Abstract available

    October 2021
  33. OVERWATER A, van Munster SN, Offerhaus GJA, Seldenrijk CA, et al
    Extension of early esophageal squamous cell neoplasia into ducts and submucosal glands and the role of endoscopic ablation therapy.
    Gastrointest Endosc. 2021;94:832-842.
    PubMed     Abstract available

    September 2021
  34. IWAMURO M, Fujii N, Tanabe S, Okada H, et al
    Desquamative esophagitis followed by esophageal cancer in a stem cell transplant recipient.
    Gastrointest Endosc. 2021 Sep 20. pii: S0016-5107(21)01650.

  35. FREI NF, Bergman JJGHM, Pouw RE
    Screening for Barrett's esophagus: Ready for prime time or still hard to swallow?
    Gastrointest Endosc. 2021;94:506-508.

  36. IYER PG, Taylor WR, Slettedahl SW, Lansing RL, et al
    Validation of a methylated DNA marker panel for the nonendoscopic detection of Barrett's esophagus in a multisite case-control study.
    Gastrointest Endosc. 2021;94:498-505.
    PubMed     Abstract available

    August 2021
  37. MONTGOMERY EA, Haidry R
    Treating esophageal squamous cell carcinoma with ablation: the fear of what lies beneath.
    Gastrointest Endosc. 2021 Aug 18. pii: S0016-5107(21)01495.

  38. XIA R, Li H, Shi J, Liu W, et al
    Cost-effectiveness of risk-stratified endoscopic screening for esophageal cancer in high-risk areas of China: a modeling study.
    Gastrointest Endosc. 2021 Aug 18. pii: S0016-5107(21)01563.
    PubMed     Abstract available

  39. KAMBOJ AK, Leggett CL
    Barrett's esophagus indefinite for dysplasia carries a definite risk of neoplasia.
    Gastrointest Endosc. 2021;94:271-272.

  40. DUPREE A, Ehlken H, Rosch T, Luken M, et al
    Laparoscopic lymph node sampling: a new concept for patients with high-risk early esophagogastric junction cancer resected endoscopically.
    Gastrointest Endosc. 2021;94:282-290.
    PubMed     Abstract available

  41. EVERSON MA, Garcia-Peraza-Herrera L, Wang HP, Lee CT, et al
    A clinically interpretable convolutional neural network for the real-time prediction of early squamous cell cancer of the esophagus: comparing diagnostic performance with a panel of expert European and Asian endoscopists.
    Gastrointest Endosc. 2021;94:273-281.
    PubMed     Abstract available

  42. PHILLIPS R, Januszewicz W, Pilonis ND, O'Donovan M, et al
    The risk of neoplasia in patients with Barrett's esophagus indefinite for dysplasia: a multicenter cohort study.
    Gastrointest Endosc. 2021;94:263-270.
    PubMed     Abstract available

    July 2021
  43. YANG LS, Holt BA, Williams R, Norris R, et al
    Endoscopic features of buried Barrett's mucosa.
    Gastrointest Endosc. 2021;94:14-21.
    PubMed     Abstract available

    June 2021
  44. BARTEL MJ, Mousa OY, Brahmbhatt B, Coffman DL, et al
    Impact of topical budesonide on prevention of esophageal stricture after mucosal resection.
    Gastrointest Endosc. 2021;93:1276-1282.
    PubMed     Abstract available

  45. SOLFISBURG QS, Sami SS, Gabre J, Soroush A, et al
    Clinical significance of recurrent gastroesophageal junction intestinal metaplasia after endoscopic eradication of Barrett's esophagus.
    Gastrointest Endosc. 2021;93:1250-1257.
    PubMed     Abstract available

  46. ZHANG M, Zhu C, Wang Y, Kong Z, et al
    Differential diagnosis for esophageal protruded lesions using a deep convolution neural network in endoscopic images.
    Gastrointest Endosc. 2021;93:1261-1272.
    PubMed     Abstract available

    May 2021
  47. MWACHIRO MM, Dawsey SM
    Larger esophageal Lugol's unstained lesions need more follow-up: size as an important predictor for risk of premalignant lesions.
    Gastrointest Endosc. 2021;93:1074-1076.

  48. DE GROOF J, Antonelli G, Dinis-Ribeiro MJ, Bergman JJ, et al
    Meta-analyses of machine learning in endoscopy: stacking apples and oranges.
    Gastrointest Endosc. 2021;93:1016-1018.

  49. LIU M, Zhou R, Guo C, Xu R, et al
    Size of Lugol-unstained lesions as a predictor for risk of progression in premalignant lesions of the esophagus.
    Gastrointest Endosc. 2021;93:1065-1073.
    PubMed     Abstract available

    April 2021
  50. BABA ER, Uedo N, Rodrigues AL, da Costa Martins B, et al
    Gastrointest Endosc. 2021 Apr 22. pii: S0016-5107(21)01313.

  51. HAIDRY R
    Endoluminal resective therapy for residual esophageal neoplasia after definitive chemoradiotherapy: Who are we helping-the patient or the endoscopist?
    Gastrointest Endosc. 2021;93:899-901.

  52. SWEI E, Wagh MS
    Endoscopic submucosal dissection in the pharynx: Let's start at the very beginning!
    Gastrointest Endosc. 2021;93:828-830.

  53. SAPP AR, Wander P, Ali U, Gong Y, et al
    The tongue: an unusual site for esophageal adenocarcinoma metastasis diagnosed with EUS-guided FNA.
    Gastrointest Endosc. 2021;93:977-978.

  54. KAHN A, Priyan H, Dierkhising RA, Johnson ML, et al
    Outcomes of radiofrequency ablation by manual versus self-sizing circumferential balloon catheters for the treatment of dysplastic Barrett's esophagus: a multicenter comparative cohort study.
    Gastrointest Endosc. 2021;93:880-887.
    PubMed     Abstract available

  55. STRUYVENBERG MR, de Groof AJ, Fonolla R, van der Sommen F, et al
    Prospective development and validation of a volumetric laser endomicroscopy computer algorithm for detection of Barrett's neoplasia.
    Gastrointest Endosc. 2021;93:871-879.
    PubMed     Abstract available

  56. HANADA Y, Wang KK
    Safety and feasibility of same-day discharge after esophageal endoscopic submucosal dissection.
    Gastrointest Endosc. 2021;93:853-860.
    PubMed     Abstract available

  57. IIZUKA T, Kikuchi D, Suzuki Y, Tanaka M, et al
    Clinical relevance of endoscopic treatment for superficial pharyngeal cancer: feasibility of techniques corresponding to each location and long-term outcomes.
    Gastrointest Endosc. 2021;93:818-827.
    PubMed     Abstract available

    March 2021
  58. KAUL V, Diehl D, Enslin S, Infantolino A, et al
    Safety and efficacy of a novel powered endoscopic debridement tissue resection device for management of difficult colon and foregut lesions: first multicenter U.S. experience.
    Gastrointest Endosc. 2021;93:640-646.
    PubMed     Abstract available

    February 2021
  59. DESAI M, Hamade N, Sharma P
    Screening for Barrett's esophagus: challenges in identifying the population at risk.
    Gastrointest Endosc. 2021;93:420-421.

  60. CHEN Z, Ng H, Liu Y, Guo C, et al
    Endoscopic submucosal dissection of early squamous cell carcinoma of the soft palate.
    Gastrointest Endosc. 2021;93:517-518.

    January 2021
  61. SUBRAMANIAN SK, Bhakta D, Thosani N
    Hepatocellular carcinoma masquerading as nodular Barrett's esophagus.
    Gastrointest Endosc. 2021 Jan 22. pii: S0016-5107(21)00038.

  62. MOLENA D, DeMeester SR
    Gastrointest Endosc. 2021;93:284-285.

  63. OTAKI F, Iyer PG
    Gastrointest Endosc. 2021;93:283-284.

  64. STRUYVENBERG MR, de Groof AJ, van der Putten J, van der Sommen F, et al
    A computer-assisted algorithm for narrow-band imaging-based tissue characterization in Barrett's esophagus.
    Gastrointest Endosc. 2021;93:89-98.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.